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ABSTRACT:Metabolic profiling of individuals with type 2 diabetes mellitus (T2DM) has previously been limited to
single-time-point samples, ignoring time-of-day variation. Here, we tested our hypothesis that body mass and
T2DM affect daily rhythmicity and concentrations of circulating metabolites across a 24-h day in 3 age-matched,
male groups—lean, overweight/obese (OW/OB), and OW/OB with T2DM—in controlled laboratory conditions,
which were not confounded by large meals. By using targeted liquid chromatography/mass spectrometry
metabolomics, we quantified 130 plasma metabolites every 2 h over 24 h, and we show that average metabolite
concentrations were significantly altered by increased body mass (90 of 130) and T2DM (56 of 130). Thirty-eight
percent ofmetabolites exhibited daily rhythms in at least 1 study group, andwhere ametabolite was rhythmic in >1
group, its peak time was comparable. The optimal time of day was assessed to provide discriminating biomarkers.
This differed between metabolite classes and study groups—for example, phospholipids showed maximal differ-
enceat 5:00AM (leanvs.OW/OB)andat 5:00 PM (OW/OBvs.T2DM).Metabolites thatwere identifiedwithboth robust
24-h rhythms and significant concentration differences between study groups emphasize the importance of con-
trolling the timeofdayfordiagnosisandbiomarkerdiscovery,offeringasignificant improvementover current single
sampling.—Isherwood, C. M., Van der Veen, D. R., Johnston, J. D., Skene, D. J. Twenty-four-hour rhythmicity of
circulating metabolites: effect of body mass and type 2 diabetes. FASEB J. 31, 5557–5567 (2017). www.fasebj.org
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It is widely accepted that obesity is themain risk factor for
type 2 diabetesmellitus (T2DM) (1). The progression from
obesity to T2DM is largely a result of comorbidities, such
as systemic inflammation and insulin resistance. Meta-
bolic profiling by using targeted metabolomics, which
enables the quantification of more than 100 low-MW in-
termediates of metabolism, is increasingly used to char-
acterize (pre)diabetic phenotypes and has identified
differences in metabolite profiles between those individ-
uals who are obese and those with T2DM (2–5).
Recent work by our group and others has shown a 24-h
variation in thehumanmetabolome inhealthy individuals,
analyzed by using a range of analytical platforms (6–12),
which has demonstrated that an estimated 15–20% of the
metabolome is rhythmic in blood (6, 7). Transgenic mice
that carry targeted genetic manipulation of circadian clock
genes also exhibit a phenotype that involves defective
metabolism, andassociations between the circadian timing
system and metabolic responses have been reported in
humans (13).Reviewsof these studies, including thehigher
incidence of obesity, T2DM, and related disorders in shift
workers, have recently been published (14, 15).
Existing metabolomics studies in T2DM have been re-
stricted to the analysis of single-time-point,mostly fasting,
samples, which cannot characterize the effect of increased
body mass and T2DM on rhythmic metabolites. Charac-
terizing 24-hmetabolite rhythms in T2DMcomparedwith
age- and body mass–matched controls may therefore
provide novel insights into the etiology andprogression of
T2DM. Identification of the optimal time of day for blood
sampling—when metabolite levels show the biggest dif-
ference betweenT2DMand controls—would also provide
more discriminating diagnostic biomarkers, rather than
taking a single morning fasting sample.
We thus assessed the effect of increased body mass
[overweight/obese (OW/OB)] andT2DMon24-h rhythms
of circulating metabolites in men by using a quantitative
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targeted liquid chromatography/mass spectrometry
(LC/MS) metabolomics approach. As T2DM is often
accompanied by obesity, we set out to distinguish the
effects of T2DM from those of increased body mass by
incorporating both a lean and an OW/OB control
group into the current study design.
MATERIALS AND METHODS
All aspects of the study were conducted in accordance with the
Declaration of Helsinki and conformed to international ethical
standards. A favorable ethical opinion was obtained from the
Surrey Research Ethics Committee and the University of Surrey
Ethics Committee.Written, informed consentwas obtained from
all participants.
Prelaboratory session
The screening process and study protocol have been described
previously (16, 17). In brief, initial screeningwas conducted via a
self-reported medical history questionnaire, and was confirmed
by the participant’s general practitioner. Participants who were
receiving medication that was known to influence the endoge-
nous circadian timing system or who had a history of hypogly-
cemic episodes or hemoglobin A1c (HbA1c) . 8.5% (69 mM)
were excluded. Additional clinical screening was performed to
assess general health, sleep patterns, and diurnal preference
(morningness/eveningness).
Effects of body mass index (BMI) and T2DM were assessed
separately within the study by using 3 study groups of men: 1)
lean, 2)OW/OB, and 3) T2DM.Participants in the lean andOW/
OB groups were matched for age and glucose homeostasis
markers (HbA1c, fasting glucose and insulin), whereas partici-
pants in the OW/OB and T2DM groups were matched for age
and BMI. Participant (n = 23) demographics for metabolomics
analyses are shown in Table 1.
Tominimize sleep debt and any effects of nutritional status or
exercise, a strict prestudy protocol was prescribed the week be-
fore study entry at the Surrey Clinical Research Centre. Partici-
pants’ in-bed time was aligned to the sleep schedule of the
laboratory session (10:30–6:30 AM), without deviation by more
than 15min.Within 90min ofwaking, participantswere asked to
obtain at least 15 min of natural outdoor light to maximize cir-
cadian entrainment. Excessive exercise was also avoided. Com-
pliance was verified by using continuously worn rest-activity
monitors (Actiwatch-L; Cambridge Neurotechnology, Cam-
bridge, United Kingdom). Alcohol and caffeine consumption
was prohibited throughout the prestudy and laboratory session.
For the first 4 d of the prestudy protocol, participants had to
consume their meals within set time windows (breakfast 7:00–
9:00AM, lunch12:00–2:00 PM, anddinner5:30–7:30 PM) (16).During
the last 3 d of the prestudy protocol, participants could only
consume food that had been provided by the research team
during these same time windows. Participants were given the
same breakfast but could choose their other meals from a set
selection of ready meals with similar macronutrient content.
Total daily food energy (;35% derived from fat) was 150% of
the basal metabolic rate using the Schofield equation (18).
Laboratory session
During the laboratory session, light intensity, physical activ-
ity, and meals were strictly controlled, as illustrated in Fig. 1.
Participants lay semirecumbent throughout. During lights on
(6:30 AM–10:30 PM), light intensity was ;600 lux in the di-
rection of gaze. During the light period, small meals, which
were composed of isocaloric Fortisip (Nutricia, Schiphol, The
Netherlands) milkshakes, were given hourly from 3:30 PM (d
1), andwater was available ad libitum. Individual food energy
intake was set at 110% of the basal metabolic rate using the
Schofield equation (18). During lights off (10:30 PM to 6:30 AM,
0 lux), participants had the opportunity to sleep.
Blood samples (n = 13 per participant) were drawn into an-
ticoagulant (dipotassium-EDTA) tubes every 2 h from7:00 AMon
d 1 for 24 h, spun (3000 g, 10 min, 4°C) to isolate plasma, and
stored at280°C until analysis.
Analysis of plasma metabolites
Samples for glucose and triglyceride (TAG) analyses were
thawed overnight at 4°C before undergoingmeasurement in the
ILab 650 Clinical Analyzer (Instrumentation Laboratory, North
Risley, United Kingdom). The combined flow injection analysis
and LC/MS targeted metabolomics analysis was performed by
using the AbsoluteIDQ p180 kit (Biocrates Life Sciences AG,
Innsbruck, Austria) and aWaters Xevo TQ-S mass spectrometer
that was coupled to an Acquity UPLC system (Waters, Milford,
MA, USA). Plasma samples (10 ml) were processed on four 96-
well plates—each plate containing all time points from at least 1
participant fromeachgroup—andweremeasuredwithin1moof
eachother.The samples on eachplatewere randomlyassigned to
minimize any effect of assay drift.
Human plasma-based quality controls (QCs) with analytes
added in 3 defined concentrations—low (QC1), medium (QC2),
and high (QC3)—were provided with the kit. Medium quality
control (QC2), repeated every 20 samples on each assay plate,
was used to calculate the intra- and interplate coefficient of var-
iation (CV%). Data were normalized between batches by using
the results of QC2 repeats across the plate (n = 4) and between
TABLE 1. Participant screening data of lean, OW/OB, and T2DM study groups
Variable Lean, n = 8 OW/OB, n = 9 T2DM, n = 6
Age (yr) 53.6 6 6.0 51.0 6 7.7 57.3 6 4.8
BMI (kg/m2) 23.2 6 1.4*** 29.8 6 2.3### 32.2 6 2.5
Waist circumference (cm) 88.9 6 6.5*** 105.1 6 3.9### 112.8 6 8.9
Glucose (mM) 4.2 6 0.7*** 4.9 6 0.7** 6.7 6 1.6
Insulin (pM) 28.1 6 16.8** 39.9 6 18.5** 110.5 6 85.3
HbA1c (%) 5.4 6 0.4*** 5.3 6 0.5*** 6.9 6 0.9
BP systolic (mmHg) 129.4 6 9.7* 133.8 6 11.1 146.8 6 10.6
BP diastolic (mmHg) 84.0 6 10.2 85.1 6 10.7 88.8 6 9.0
Data are given as means 6 SD. BP, blood pressure. *P , 0.05, **P , 0.01, ***P , 0.001 vs. T2DM;
###P , 0.001 vs. lean (1 way ANOVA, Tukey post hoc test).
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plates (n = 4) usingMETIDQ software (QC2 correction; Biocrates
Life Sciences AG).Metabolites were excluded if the CV%of QC2
was.30%or if all 3 groups contained.25%ofsamples thatwere
below the limit of detection, below the lower limit of quantifi-
cation, or above the limit of quantification or blank out of range
(n = 54 excluded) (19). Intraplate CV% of the remaining 130
quantified metabolites was 4.8 6 0.3% (mean 6 SEM) and inter-
plate CV% was 10.2 6 0.5% (mean 6 SEM). Quantified metabo-
lites were composed of 20 amino acids and 9 biogenic amines
measured by LC/MS (7-point calibration using isotope-labeled
internal standards) and 10 acylcarnitines, 13 lysophosphati-
dylcholines (lysoPCas), 30 diacylphosphatidylcholines (PCaas),
34 acyl-alkyl-phosphatidylcholines, 9 sphingomyelins (SMs),
and 5 hydroxysphingomyelins measured by flow injection
analysis (1-point calibration using isotope-labeled internal stan-
dards for acylcarnitines or unlabeled internal standards for lip-
ids). Lipids were quantified by using nonphysiologic lipids as
internal standards, 2 for PCs, 1 for lysoPCs, and 1 for sphingoli-
pids. As a result of the unavailability of isotope-labeled lipid
standards, quantification, but not precise identification, was
possible (lipid signals measured with the AbsoluteIDQp180 kit
having a number of possible isobars and/or isomers).
Data analysis
To assess 24-h metabolite rhythmicity, we performed cosinor
analysis on mean z-score values—z score calculated across 24 h
per individual (12)—for all participants. Peak time (acrophase),
amplitude, and significance of a cosine fit (P , 0.05) were de-
termined in each case (Matlab 2013b; MathWorks, Natick, MA,
USA). Principal component analysis and orthogonal partial least
squares discriminant analysis (OPLS-DA; SIMCA-P v.13.0 soft-
ware; Umetrics, Malmo, Sweden) models (lean vs.OW/OB and
OW/OB vs. T2DM) were used to identify metabolites with the
mostvariancebetweenstudygroups.Validationof theOPLS-DA
models was provided by permutation analysis (999 permuta-
tions) and a CV ANOVA P value of the model. Differences in
individual metabolite levels were analyzed in R (version 3.2.2;
The R Foundation, Vienna, Austria) using the aov function in the
statistics package (19). Linear models were fitted to the study
group and time of day (13 time points, repeated measures per
individual), with individual participants as covariates. Signifi-
cant differences between study group, time of day, and their
interaction were determined by using 2-way ANOVA. Signifi-
cance values were corrected for multiple comparisons according
to the Benjamini-Hochberg false discovery rate (FDR). Differ-
ences between metabolites were considered significant with an
FDR ,0.05. Missing values (n = 16; 5.4%) were left blank and
were not taken into account for both the univariate and multi-
variate analyses.Missingvalueswerenot clustered inaparticular
sampling time (no time point had.4 missing samples) or study
group (n = 7, 5, and 4 in lean, OW/OB, and T2DM groups, re-
spectively). The timepoint atwhichmostmetaboliteswithin each
class had the maximum concentration difference between lean
and OW/OB groups and between OW/OB and T2DM groups
was calculated by using absolute values and illustrated in po-
lar plots by using R. We performed quantitative enrichment
analysis (lean vs. OW/OB and OW/OB vs. T2DM) by using
MetaboAnalyst 3.0 (www.metaboanalyst.ca) (20).
RESULTS
To assess the effect of increased bodymass, we compared
the OW/OB group with the lean group, both of which
werematched for glucose homeostasis. Comparison of the
OW/OB and T2DM groups enabled us to compare the
effect of T2DM per se in weight-matched groups. Table 1
presents the screening demographic data for the 3 study
groups.TheT2DMgrouphadsignificantlyhigherglucose,
insulin, and HbA1c than both the OW/OB and lean
groups (Table 1).
Assessment of daily rhythmicity, as determined by
cosinor analysis of 24-h metabolite profiles, identified
50 (38%) of 130metabolites with significant daily rhythms
(P, 0.05) in at least oneof the studygroups (Fig. 2), 84%of
which peaked during lights on. Fourteen (28%) of these
50metabolitesdisplayed24-hdaily rhythms inall 3groups,
namely, citrulline, proline, sarcosine, symmetrical dime-
thylarginine, acetylcarnitine, AC-C3 (propionylcarnitine),
butyrylcarnitine, hexadecanoylcarnitine, 43 lysoPCa
(C18:1, C18:2, C20:3, and C20:4), and 23 PCaa (C32:1
and C36:5). The 24-h profiles of these rhythmic metab-
olites are shown in Fig. 3. An additional 11 (22%) of
50 metabolites, namely, alanine, glycine, isoleucine,
tyrosine, valine, a-aminoadipic acid (a-AAA), AC-C18:
1 (octadecenoylcarnitine), PCaa (C36:1, C36:3, C40:2),
and acyl-alkyl-phosphatidylcholine (C36:2) displayed
daily rhythms in the lean and OW/OB groups, but not
in the T2DM group, whereas 5 (10%) of 50 metabolites
displayed daily rhythms in the OW/OB and T2DM
groups, but not in the lean group, namely, tetradece-
noylcarnitine and octadecanoylcarnitine, 23 lysoPCa
(C16:0 andC18:0), and PCaa (C36:2). Also shown in Fig.
2, 20 (40%) of 50metabolites displayed adaily rhythm in
only 1 study group. Where a metabolite was rhythmic
Figure 1. Study protocol. Participants (n = 23) entered the clinical laboratory at 3:00 PM on d 1 and lay semirecumbent throughout.
The next day (d 2), during the light period from 6:30 AM to 10:30 PM (;600 lux, in direction of gaze), participants were given hourly
isocaloric milkshakes that commenced at 6:30 AM and water was available ad libitum. During the dark period (10:30 PM to 6:30 AM,
0 lux), they had the opportunity to sleep. Blood was drawn every 2 h from 7:00 AM on d 2 until 7:00 AM the next day (d 3).
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in .1 group [n = 30 (60%) of 50], its peak time was
comparable between groups (within 2 h), with the ex-
ception of valine (6-h difference). Peak times of these
metabolite rhythms are illustrated in Fig. 2 and are
further detailed (peak time and amplitude) in Supple-
mental Table 1. There were no significant differences in
the amplitude of metabolite rhythms between study
groups. In addition to the panel of metabolites mea-
sured, plasma glucose concentrations displayed a sig-
nificant cosine rhythm in the lean group only (P, 0.05),
with a peak time of 15.02 h, and TAG displayed sig-
nificant 24-h rhythms in theOW/OB and T2DMgroups
(P , 0.05), with peak times of 15.80 and 14.13 h,
respectively.
A principal component analysis of all samples—130
metabolites, 13 time points, and 285 observations—was
performed [R2X (cumulative), 0.877; Q2 (cumulative),
0.736; n = 16 components]. The OPLS-DA score plot of the
lean and OW/OB groups in Fig. 4A demonstrates a clear
separation of the 2 groups [R2X (cumulative), 0.636; R2Y
(cumulative), 0.913; Q2 (cumulative), 0.886; n = 5 com-
ponents, validated by permutation analysis; intercepts:
R2 = 0.0, 0.187; and Q2 = 0.0, 20.435; and CV ANOVA
P value lean vs. OW/OB, P = 2.12285]. Variance within
the model that was revealed in the loading plot (Fig.
4B) illustrates that the amino acids, biogenic amines,
and acylcarnitines were mainly negatively correlated,
whereas the phospholipids were mainly positively
correlated within the model. The OPLS-DA score plot
of the OW/OB and T2DM groups also demonstrates
a clear separation of the groups [R2X (cumulative),
0.658; R2Y (cumulative), 0.913; Q2 (cumulative), 0.879;
n = 5 components, validated by permutation analysis;
intercepts:R2 = 0.0, 0.202; andQ2 = 0.0,20.478; andCV
ANOVA P value OW/OB vs. T2DM, P = 7.60275; Fig.
4C]. In contrast, there was no obvious pattern in the
variance between the OW/OB and T2DM groups
according to metabolite class in the loadings plot (Fig.
4D). P (loading) values of all of the metabolites in both
OPLS-DA models are shown in Supplemental Table 2.
We performed 2-way ANOVA (study group and
time of day as factors) to assess the effect of increased
body mass and T2DM on metabolite 24-h concentra-
tions. Mean 6 SEM concentrations (micromolar) of the
metabolites measured in the lean, OW/OB, and T2DM
groups and of the metabolites with significant group
differences (FDR , 0.05) between lean and OW/OB
groups and OW/OB and T2DM groups are shown in
Supplemental Table 3. Ninety metabolites (69%) were
significantly different between the lean and OW/OB
groups (FDR , 0.05), 70 (78%) of 90 had significantly
lower concentrations in the OW/OB group, comprising
mainly phospholipids [66 (94%) of 70], which confirmed
the patterns that were observed in the OPLS-DA (Fig. 4).
Figure 2. Metabolites with a signiﬁcant cosine rhythm in the 3 study groups. A) Venn diagram showing the metabolites (name
and number) with a signiﬁcant cosine rhythm in the lean, OW/OB, and T2DM groups. B) Peak times of the metabolites with a
signiﬁcant cosine rhythm in more than 1 study group is also displayed. Peak time of day for each metabolite in the lean (red
circle), OW/OB (blue square), and T2DM (black triangle) groups is shown. The dark condition (10:30 PM to 6:30 AM, 0 lux) is
illustrated on the graph as a gray-shaded area, and time of day (hour) is displayed on the x axis.
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Quantitative enrichment analysis indicated that tyrosine
metabolism (3-fold enrichment, P = 0.075), catechol-
amine biosynthesis (3-fold enrichment, P = 0.075), and
phenylalanine and tyrosine metabolism (2-fold enrich-
ment, P = 0.120) were the top 3 pathway-associated
metabolite sets related to increased body mass. None of
these pathways, however, was significantly enriched
(P . 0.05).
When comparing T2DM and OW/OB groups, 56
(43%) of 130 metabolites demonstrated significant dif-
ferences in concentration between the 2 groups (Sup-
plemental Table 3). More than 60% of thesemetabolites
[34 (61%) of 56] had significantly higher concentrations
in T2DM, namely, amino acids (alanine, phenylalanine,
glutamate, proline, and tyrosine), biogenic amines
[a-AAA, sarcosine, trans-4-hydroxyproline (t4-OH-
Pro)], acylcarnitines (AC-C0, AC-C3), 223 PC, and 2
sphingolipids (SM C20:2 and SM C26:1). Metabolites
with significantly lower concentrations in T2DM
[22 (39%) of 56] were glutamine, histidine, ornithine,
serine, AC-C18 (octadecanoylcarnitine), AC-C18:1,
octadecadienylcarnitine, 53 lysoPC, 83 PC, and 2
sphingolipids [SM C16:0 and SM(OH)C16:1]. The 24-h
profiles of the metabolites with significant concentration
differences between the T2DM group and OW/OB con-
trols are shown in Fig. 5. The top 4 metabolite pathways
that were associated with T2DM (between the OW/OB
and T2DM study groups) were histidine metabolism
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Figure 3. Metabolites with daily 24-h rhythms in all study groups. Metabolites with signiﬁcant cosinor rhythms (n = 14) in the lean
(red), OW/OB (blue), and T2DM (black) groups peak at a similar time of day, with no signiﬁcant difference in relative
amplitude. Relative concentration (z score) is displayed on the y axis, values are mean 6 SEM. The dark condition (22:30–06:30 h,
0 lux) is illustrated on the graph as a gray-shaded area, and time of day (h) is displayed on the x axis.
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(4-fold enrichment, P = 0.036), pyrimidine metabolism
(2.5-fold enrichment, P = 0.123), purine metabolism (2.5-
fold enrichment, P = 0.123), and glutamate metabolism
(2.5-fold enrichment, P = 0.123). After FDR correction,
the histidine metabolism pathway was not significantly
enriched.
Figure 5 also shows the 24-h profiles of glucose and
TAG. The 24-h average glucose levels were significantly
higher (P, 0.001) in the T2DMgroup (mean6 SEM, 7.746
0.32 mM) compared with the OW/OB group (6.536 0.15
mM) and lean controls (6.086 0.6 mM). The 24-h average
TAG concentrations were significantly lower (P, 0.01) in
the T2DM group (1.43 6 0.05 mM) compared with the
OW/OB group (1.72 6 0.23 mM), and were significantly
higher (P , 0.001) in the OW/OB group compared with
lean controls (1.156 0.04 mM).
Figure 4. OPLS-DA plots separated according
to study group. A) Score plot of lean (red) vs.
OW/OB (blue) groups; R2X (cumulative),
0.636; R2Y (cumulative), 0.913; and Q2 (cumu-
lative), 0.886 (validated by permutation analy-
sis). B) Score plot of OW/OB (blue) vs. T2DM
(black) groups; R2X (cumulative), 0.658; R2Y
(cumulative), 0.913; and Q2 (cumulative), 0.879
(validated by permutation analysis). C) Loading
plot of lean vs. OW/OB groups where negative
P (loading) values represent metabolites with
higher concentrations, and positive P (loading)
values represent metabolites with lower con-
centrations in OW/OB compared with the lean
group. Every ﬁfth metabolite is labeled on the
x axis. D) Loading plot of OW/OB vs. T2DM
groups where negative P (loading) values
represent metabolites with higher concentra-
tions, and positive P (loading) values represent
metabolites with lower concentrations in T2DM
compared with the OW/OB group. Only
metabolites whose error bars did not span the
x axis have been plotted. Every second metab-
olite is labeled on the x axis. Metabolites are
colored according to class; amino acids and
biogenic amines (blue), acylcarnitines (green),
PCaa (yellow), acyl-alkyl-phosphatidylcholine
(PCae; light orange), lysoPC (dark orange),
and sphingomyelin (brown). For a full list of all
metabolites and their corresponding P (load-
ing) values, see Supplemental Table 2.
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Six metabolites—proline, sarcosine, AC-C3, lysoPCa
(C18:1 and C18:2), and PCaa (C36:5)—were affected by
body mass, T2DM, and time of day (i.e., had robust daily
rhythms in every studygroupandsignificant concentration
differences between studygroupsand their controls). These
were the only metabolites with significant differences in
concentration between study groups that also exhibited
significant24-hcosine rhythms inmostof theparticipants in
Figure 5. Twenty-four-hour proﬁles of metabolites, glucose, and TAG with signiﬁcant concentration differences between OW/OB
and T2DM study groups. Mean 6 SEM concentrations of all amino acids (n = 9), biogenic amines (n = 3), acylcarnitines (n = 5),
and the most signiﬁcantly different phospholipids in the lean (red), OW/OB (blue), and T2DM (black) study groups are shown.
Concentration (micromolar for metabolites and millimolar for glucose and TAG) is shown on the y axis. The dark condition
(10:30 PM to 6:30 AM, 0 lux) is illustrated on the graph as a gray-shaded area, and time of day (h) is displayed on the x axis.
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all study groups. Proline, sarcosine, and AC-C3 had sig-
nificantly higher concentrations in the OW/OB group
compared with the lean group that were significantly
higher still in the T2DMgroup comparedwith theOW/OB
group. Lysophosphatidylcholines (C18:1 and C18:2) had
significantly lower concentrations in the OW/OB group
comparedwith the leangroup thatwere significantly lower
still in theT2DMgroup comparedwith theOW/OBgroup.
Diacylphosphatidylcholine (PCaaC36:5)didnot followthis
pattern, its concentrations being significantly lower in the
OW/OB group compared with the lean group and signif-
icantly higher in the T2DMgroup comparedwith theOW/
OB group.
In addition to the effect of bodymass and T2DM,more
than one half of themetabolites [80 (61%) of 130] exhibited
a significant variation with time of day (ANOVA, FDR,
0.05; Supplemental Table 3). No metabolites showed a
significant time of day 3 group interaction, with the ex-
ception of lysoPCa 16:1 (lean vs. OW/OB group). We
calculated the time point that best distinguished concen-
trationdifferences between studygroups.Metabolites that
had significant concentration differences in both the OW/
OB group compared with lean controls and the T2DM
group comparedwithOW/OB controls—comprising one
thirdof themetabolites [n=40 (31%)of 130]—wereused to
determine the optimal sampling time. Concentration dif-
ferences for thesemetabolites at each timepoint across 24h
are plotted asheatmaps (Fig. 6) and show the optimal time
of day for sampling tomaximize concentration differences
between groups. For each metabolite, the time point at
which its concentration differed the most between study
groups is included in Supplemental Table 3. We also cal-
culated the time point at which most metabolites within
each class had the maximum concentration difference be-
tween study groups. The polar plot of these data that
compares the lean and OW/OB groups (Supplemental
Fig. 1A) illustrates that 30% of the amino acids and bio-
genic amines classes (combined) had their maximum dif-
ferences in concentration at 1:00 AM. In contrast, 30% of
acylcarnitines had their maximum differences at 1:00 PM
and 45% of the phospholipids had their maximum dif-
ferences at 5:00 AM. Comparing the OW/OB and T2DM
groups (Supplemental Fig. 1B), 20%of theaminoacids and
biogenic amines (combined) had their maximum differ-
ences in concentration at 1:00 and 7:00 AM. In contrast, 40%
of acylcarnitineshadtheirmaximumdifferences at23:00h,
and 30%of phospholipids had theirmaximumdifferences
at 5:00 PM, 10 and 12 h different from the lean andOW/OB
groups, respectively. The optimum time of day to detect
differences between study groups thus differed according
tometabolite class and the study groups being compared.
DISCUSSION
This study, to our knowledge, is the first to independently
map the effects of increased bodymass and the combined
effects of obesity and T2DMon 24-h plasmametabolite
rhythms in men. Rhythmic metabolites were observed
in all study groups (lean, n = 35; OW/OB, n = 39; T2DM,
n = 20), 84% ofwhich peaked during lights on.Metabolites
that demonstrated significant daily rhythms are involved
in the biochemical pathways that underlie T2DMandhave
been proposed as biomarkers (e.g., branched chain amino
acids, short chain acylcarnitines, a-AAA) (21–25). The ro-
bust time-of-day variation that was observed in the me-
tabolite profiles highlights that timeof day shouldbenoted
and controlled for clinical sampling, biomarker discovery,
and interpretation of T2DMmetabolomics studies.
Metabolites that exhibit significant cosine rhythms in
more than 1 studygroup (n= 30) peaked at approximately
the same time of day, thus suggesting that the timing of
metabolite rhythms is not significantly affected by in-
creased body mass or T2DM. This lack of change in the
timing of metabolite rhythms is in agreement with our
earlier work that showed no change in the timing of the
plasma melatonin and leptin rhythms in these study
groups (17). Similarly, there was no significant difference
in the amplitude of the rhythmic metabolites between
study groups. This finding contrasts with reports of at-
tenuatedgene expression circadian rhythmicity in adipose
tissue in mouse models of obesity and T2DM (26) and in
leukocytes of patients with T2DM (27). The disparity be-
tween the attenuated rhythms observed in gene expres-
sion and the retention of plasma metabolite rhythms in
obesity and T2DM likely reflects the homeostatic mecha-
nisms and multiple regulatory pathways that are present
in the circulation. The comparable robust metabolite
rhythms that were observed in both the OW/OB and
T2DM groups indicate that no general rule of reduced
amplitude from lean to obese to T2DM can be made.
Daily rhythms in plasma metabolites have previously
been characterized in lean, youngmale study participants
by using the same targeted LC/MS-based metabolomics
approach (12). Of the 171 metabolites measured in that
study, 109 (64%) exhibited a diurnal rhythm compared
with only 27% rhythmic metabolites in the lean group in
the present study. Although the participants in both
studies had similar sleep-wake times, participants in the
study by Davies et al. (12) had regular meals—breakfast,
lunch, dinner, evening snack—rather than the hourly
isocaloricmeals in the present study,which resulted in set,
imposed postprandial changes in circulating metabolites.
In the present study, choosing to administer hourly iso-
caloric meals during the light period provided the op-
portunity to test postabsorptive metabolism while
removing the imposed effects of largemeals onmetabolite
profiles. Despite these differences in study protocols, sig-
nificant 24-h cosine rhythmswere observed in some of the
samemetabolites of the study by Davies et al. (12) and the
lean group of the present study, namely, isoleucine, pro-
line, valine, kynurenine, symmetrical dimethylarginine,
sarcosine, a-AAA, acetylcarnitine, butyrylcarnitine, hex-
adecanoylcarnitine, AC-C18:1, lysoPCa C18:2, PCaa C40:2,
PCaa C42:2, and SMC20:2. Both glucose and TAG levels
peaked in the afternoon,which is in agreementwith earlier
studies under similar, regular, small meal feeding condi-
tions (28), and are most likely a result of insulin resistance
in the afternoon. Whereas nutritional status undoubtedly
affects circulating metabolite levels, there is also evidence
to suggest that some of these metabolites are under circa-
dian clock control—rhythmic expression being present in
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laboratory constant routine conditions that are optimized
to reveal endogenous circadian rhythms (8, 9, 11, 28).
Previous studies that have compared the metabolic
profiles of individuals who went on to develop T2DM
with those that did not have helped to uncover novel
T2DM biomarkers (21–25). Although not all studies
identified the same metabolites, a T2DM metabolic phe-
notype may include higher concentrations of alanine,
glutamate, phenylalanine, tyrosine, a-AAA, t4-OH-Pro,
and branched-chain amino acids (leucine, isoleucine, and
valine), as well as lower concentrations of glycine, serine,
and glutamine. Of note, in the present study, significantly
higher alanine, phenylalanine, a-AAA, and t4-OH-Pro
levels, as well as lower glutamine and serine levels were
only observed in T2DM compared with the OW/OB
group and, therefore, may arise independently of in-
creased body mass. Individuals with a-AAA concentra-
tions in the top quartile show the strongest association
with diabetes risk, high a-AAA levels being associated
with insulin resistance and impaired b-cell function (24).
Elevated a-AAA levels are associated with low concen-
trations of glutathione, likely as a result of inflammation
Figure 6. Heatmaps showing optimal time of day
for maximizing sampling differences between
study groups. A) Time points of maximum
(yellow) or minimum (blue) concentration
difference between OW/OB and lean groups
across 24 h. B, C) Time points of maximum
(yellow) or minimum (blue) concentration
difference between T2DM and OW/OB groups
across 24 h. The dark condition (10:30 PM to
6:30 AM, 0 lux) is illustrated on the x axis as a gray-
shaded area.
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and oxidative stress, which are common comorbidities of
T2DM (21) that are consistent with the raised a-AAA
levels in our T2DM group. Elevated daytime a-AAA
concentrations also resulted in loss of the a-AAA rhythm
in the T2DM group. Alterations in the shape of the 24-h
profiles, which resulted in loss of the cosine rhythm, in
some key amino acids that are involved in T2DM—
namely, alanine, glycine, isoleucine, tyrosine, and
valine—suggest defective 24-h processing in T2DM that
requires additional study.
Metabolites that demonstrated significant changes in
OW/OB compared to the lean group, and in T2DM
compared to the OW/OB group could be on a continuum
from lean to obesity to T2DM. For example, in the current
study, significantly higher short-chain acylcarnitine (AC-
C0 and AC-C3) levels were observed in the OW/OB and
T2DM groups. Similar findings have also been reported
previously (29), with higher acylcarnitine concentrations
possibly resulting from excessive nonesterified fatty acid
(NEFA) availability, reduced NEFA oxidation, or both, as
malonyl-CoA inhibition of carnitine palmitoyltransferase
1 slows the transfer of NEFA into the mitochondria (29).
T2DM had no consistent effect on phospholipids, with
both higher (n = 22) and lower levels (n = 13) in the T2DM
group compared with the OW/OB control group. The
effect of T2DM on specific phospholipid species varies
between metabolomics studies, so much so that a meta-
analysis could not be performed on the lipid class as
a result of high interstudy inconsistency (25). Plasma
lysoPCs were negatively associatedwith BMI and plasma
insulin concentrations, but had no relationship with glu-
cose and the homeostatic model assessment-insulin re-
sistance, which suggests that adiposity underlies the
observed changes rather than insulin resistance or T2DM
(5); however, in the current study, lysoPC responses seem
to be more consistent—lysoPCs with significant group
differences had lower levels in the OW/OB group that
were lower still in T2DM, which suggests that they are
affected by both weight and T2DM. Rhythmic lysoPCs
also displayed robust rhythms, with the exception of
C26:1, that all peaked in the evening.
We performed quantitative enrichment analysis; how-
ever, no pathways were identified as being significantly
over-representedafterFDRcorrection. Severalmetabolites
that exhibited robust daily rhythms in the majority of
participants in all study groups and that also showed a
significant progressive change in concentration from lean
to OW/OB to T2DM groups were identified. These me-
tabolites, namely, proline, sarcosine, AC-C3, and lysoPCa
(C18:1 and C18:2), may play a role or act as biomarkers in
the progression from a healthy weight to obese with
T2DM. These metabolites are worthy of future study to
identify underlying mechanisms and to increase our un-
derstanding of the interaction between T2DM and the
circadian timing system.
The time series sampling also afforded the opportunity
to examine the optimum sampling time at which to best
distinguish differences between study groups. For each
metabolite, anoptimumtimeof collectionwasdetermined
toprovidebetterdiscriminatingbiomarkers. The rhythmic
nature of most metabolites meant that the best sampling
time differed depending on the metabolite, metabolite
class, and the study groups being compared.Weobserved
some largedifferences (10–12h)between studygroups, for
example, acylcarnitines showedmaximal difference at 1:00
(lean vs. OW/OB) and at 11:00 PM (OW/OB vs. T2DM),
and phospholipids showedmaximal difference at 5:00 AM
(lean vs.OW/OB) and at 5:00 PM (OW/OB vs. T2DM). In
contrast, the optimum sampling time for amino acids and
biogenic amines was 01:00 h, irrespective of the study
groups being compared.Despite being unable to generate
any general rules for the optimum sampling of metabo-
lites, it is interesting to note that none of the metabolite
classes exhibited its maximum concentration differences
between 7:00 AM and 11:00 PM,when samples are typically
drawn for diagnostic and research purposes. These find-
ings highlight the importance of controlling the time of day
and highlight the value of metabolic profiling across 24 h.
CONCLUSIONS
To our knowledge, this is the first time a 24-h time series of
plasma metabolites has been simultaneously assessed in
T2DM compared with an age- and weight-matched con-
trol group during a controlled daily routine. It is clear that
many aspects of the altered metabolome in T2DM exhibit
24-h diurnal variation, which has previously been over-
looked in studies that used only single samples that were
takenatapoorlydefined timepoint.Our results reveal that
the effect of body mass and T2DM on the rhythmic
metabolome vary in a metabolite-specific manner. Fur-
thermore, our findings highlight how the time of day
regulates metabolite differences between lean, OW/OB,
and T2DM phenotypes. These data thus increase our un-
derstanding of the interactions between circadian and
metabolic physiology and will inform the experimental
design of future studies.
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